PD-L1 Expression and CD8

Adjuvants, Immunologic / therapeutic use Androgen Antagonists / therapeutic use B7-H1 Antigen / metabolism Biomarkers, Tumor / metabolism CD8-Positive T-Lymphocytes / metabolism Disease Progression Disease-Free Survival Humans Lymph Nodes / pathology Lymphatic Metastasis Male Neoplasm Recurrence, Local / epidemiology Prostatectomy Prostatic Neoplasms / pathology Retrospective Studies
B lymphocytes Biomarker Immune checkpoint Lymph node metastasis PD-L1 Progression Prostate cancer Radical prostatectomy Recurrence T lymphocytes

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
03 2019
Historique:
received: 04 05 2017
accepted: 25 05 2017
pubmed: 30 7 2017
medline: 18 12 2019
entrez: 30 7 2017
Statut: ppublish

Résumé

Prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy are at higher risk of tumor recurrence and receive immediate androgen deprivation therapy (ADT). While approximately 30% of these patients do not experience recurrence, others experience disease recurrence despite ADT, and currently no biomarkers can accurately identify them. We analyzed tumors from 51 patients with node-positive prostate cancer using immunohistochemistry to investigate whether expression of the immune checkpoint ligand PD-L1 by tumor cells or the density of CD8

Identifiants

DOI: 10.1016/j.euf.2017.05.013 PMID: 28753812
pubmed: 28753812
pii: S2405-4569(17)30151-7
doi: 10.1016/j.euf.2017.05.013
pii:
doi:

Substances chimiques

Adjuvants, Immunologic 0
Androgen Antagonists 0
B7-H1 Antigen 0
Biomarkers, Tumor 0
CD274 protein, human 0

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

192-196

Informations de copyright

Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Florent Petitprez (F)

INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; UPMC University Paris 6, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.

Nicola Fossati (N)

Unit of Urology and URI, Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; NET-IMPACT, IRCCS Ospedale San Raffaele, Milan, Italy.

Yann Vano (Y)

INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; UPMC University Paris 6, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; Department of Medical Oncology, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.

Massimo Freschi (M)

NET-IMPACT, IRCCS Ospedale San Raffaele, Milan, Italy; Unit of Pathology, Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.

Etienne Becht (E)

INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; UPMC University Paris 6, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

Roberta Lucianò (R)

NET-IMPACT, IRCCS Ospedale San Raffaele, Milan, Italy; Unit of Pathology, Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.

Julien Calderaro (J)

INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; UPMC University Paris 6, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

Tiffany Guédet (T)

INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; UPMC University Paris 6, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

Laetitia Lacroix (L)

INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; UPMC University Paris 6, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

Paola M V Rancoita (PMV)

University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy.

Francesco Montorsi (F)

Unit of Urology and URI, Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; NET-IMPACT, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Wolf Herman Fridman (WH)

INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; UPMC University Paris 6, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

Catherine Sautès-Fridman (C)

INSERM, UMR_S 1138, Cordeliers Research Center, Team Cancer, Immune Control and Escape, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; UPMC University Paris 6, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

Alberto Briganti (A)

Unit of Urology and URI, Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; NET-IMPACT, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: briganti.alberto@hsr.it.

Claudio Doglioni (C)

NET-IMPACT, IRCCS Ospedale San Raffaele, Milan, Italy; Unit of Pathology, Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Matteo Bellone (M)

NET-IMPACT, IRCCS Ospedale San Raffaele, Milan, Italy; Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: bellone.matteo@hsr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Adjuvants immunologiques › PD-L1 Expression and CD8
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Antagonistes des androgènes › PD-L1 Expression and CD8
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › PD-L1 Expression and CD8
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › PD-L1 Expression and CD8
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › PD-L1 Expression and CD8
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › PD-L1 Expression and CD8
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › PD-L1 Expression and CD8
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PD-L1 Expression and CD8
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système lymphatique › Tissu lymphoïde › Noeuds lymphatiques › PD-L1 Expression and CD8
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Métastase lymphatique › PD-L1 Expression and CD8
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › PD-L1 Expression and CD8
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie urogénitale › Procédures de chirurgie urologique › Procédures de chirurgie urologique masculine › Prostatectomie › PD-L1 Expression and CD8
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › PD-L1 Expression and CD8
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › PD-L1 Expression and CD8